Testing upadacitinib for stable vitiligo
Treatments studied
Part of Skin clinical trials.
This trial tests a daily pill (upadacitinib) to see if it can improve vitiligo after an initial treatment (NECS). It is for people whose vitiligo is stable and covers a limited area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You have non-segmented vitiligo (white patches on both sides of your body) and it has been stable for at least a year
- Your vitiligo covers no more than 30% of your body
- You have not used certain treatments (like laser, phototherapy, or specific oral medications) for vitiligo within the last month
- You have no active infections, hepatitis, HIV, or tuberculosis, and your liver and kidneys are working well
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a type of light therapy (narrow-band UVB) to a daily pill called ritlecitinib works better than the pill alone for treating vitiligo. It may help if you have non-segmental vitiligo covering a moderate amount of skin.
This trial tests whether adding short bursts of steroid pills to a skin cell transplant procedure can improve results for people with stable vitiligo on hard-to-treat areas like elbows and knees.
This Phase 2 trial tests whether a new drug called D-2570 can help restore skin color in people with non-segmental vitiligo (when white patches appear randomly across the body). The study will track how well the drug works and check if it's safe to use.
This trial tests an oral medication called zasocitinib to see if it can help repigment skin in adults with nonsegmental vitiligo. It may be an option for people whose vitiligo covers a moderate amount of their body and who have not had certain recent treatments.
This trial tests a new oral medication called ACT-777991 to see if it is safe and can help repigment skin in adults with non-segmental vitiligo (the most common type that affects both sides of the body). Participants must have at least a certain amount of pigment loss on the face and total body, and agree not to use other vitiligo treatments during the study.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.